The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Trimethylamine-N-Oxide, a Metabolite Associated with Atherosclerosis, Exhibits Complex Genetic and Dietary Regulation
Open accessAbstract
Circulating trimethylamine-N-oxide (TMAO) levels are strongly associated with atherosclerosis. We now examine genetic, dietary, and hormonal factors regulating TMAO levels. We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO. Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1. FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing FMO3 decreases TMAO levels. In both humans and mice, hepatic FMO3 expression is reduced in males compared to females. In mice, this reduction in FMO3 expression is due primarily to downregulation by androgens. FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor. Analysis of natural genetic variation among inbred strains of mice indicates that FMO3 and TMAO are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intestinal microbiota convert the choline moiety of dietary phosphatidylcholine into trimethylamine, which is subsequently converted into TMAO by hepatic flavin-containing monooxygenases (Fig. 3).20–23”
From Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk (2013) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intestinal microbiota convert the choline moiety of dietary phosphatidylcholine into trimethylamine, which is subsequently converted into TMAO by hepatic flavin-containing monooxygenases (Fig. 3).20–23”
From Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk (2013) · cites this paper as [20]
Experimental — accuracy not yet measuredIn the citing paper
“TMAO is derived primarily from dietary choline and carnitine through the action of gut microbiota, which metabolize these constituents to trimethylamine (TMA).1, 11, 12 TMA is absorbed in turn and travels via the portal circulation to the liver, where it is oxidized by flavin‐containing monoxygenases, primarily FMO3, to TMAO.1, 11, 12”
From Trimethylamine N‐Oxide Promotes Vascular Inflammation Through Signaling of Mitogen‐Activated Protein Kinase and Nuclear Factor‐κB (2016) · cites this paper as [12]
In the citing paper
“In contrast, examination of hepatic FMO enzyme activity, which is responsible for converting TMA into TMAO (Wang et al., 2011; Bennett et al., 2013), revealed no significant differences between both donor mouse strains, and among the various recipient groups post cecal microbial transplantation (Figure S6, panel B).”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Bennett et al., 2013
In the citing paper
“host hepatic FMO3, the primary FMO responsible for TMAO production”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Bennett et al., 2013
In the citing paper
“important regulators in host lipid and sterol metabolism, as well as atherosclerosis development”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Bennett et al., 2013
In the citing paper
“Multiple lines of evidence show the meta-organismal pathway involved in TMAO production is mechanistically linked to atherosclerosis susceptibility (Bennett et al., 2013; Gregory et al., 2015; Koeth et al., 2013; Wang et al., 2011).”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Bennett et al., 2013
In the citing paper
“Further investigations revealed that TMAO levels help to explain a significant portion of atherosclerosis aortic root development across multiple different inbred strains of mice, and that TMAO levels are influenced by hepatic Fmo3, which is under complex control, including regulation by the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor (54).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [54]
In the citing paper
“Further, FMO3 overexpression in mice significantly increased plasma TMAO levels, while silencing FMO3 decreased TMAO levels (54).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [54]
In the citing paper
“The conversion from TMA to TMAO requires an oxidation step that is mediated by host enzyme machinery in the form of FMOs (54,(78)(79)(80)(81).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [54]
In the citing paper
“In both humans and mice, hepatic FMO3 expression was observed to be reduced in males compared with females (25,54) and could be induced by dietary bile acids through a mechanism that involves FXR (54).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [54]
In the citing paper
“FMO1, FMO2, and FMO3 were all capable of forming TMAO, though the specific activity of FMO3 was at least 10-fold higher than that the other FMOs (54).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [54]
In the citing paper
“Recent studies among multiple different inbred strains of mice in a “mouse diversity panel” linked variations in strain and sex to hepatic expression/activity of FMO3, TMAO levels, and atherosclerosis (54).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [54]
In the citing paper
“Gut microbe-produced TMA reaches the liver rapidly via the portal circulation, where a cluster of hepatic FMO enzymes efficiently oxidizes TMA into TMAO (54,82).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [54]
In the citing paper
“phosphatidylcholine, the major dietary source of choline, and the gut microbe-dependent metabolite, trimethylamine N -oxide (TMAO), 4 are both mechanistically linked to atherosclerosis development (5, 6, 8)”
From Transmission of Atherosclerosis Susceptibility with Gut Microbial Transplantation (2015) · cites this paper as [8]
In the citing paper
“Elevated TMAO has been observed in patients with cardiovascular disease and atherosclerosis, highlighting a potential downside to increased protein intake.[15-17,22, 37]”
From The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level (2018) · cites this paper as [37]
In the citing paper
“TMAO is a small organic compound, mainly derived from choline (found in foods such as red meat, fish, poultry, and eggs), which is metabolized to produce trimethylamine (TMA) by microbiota1, 4 and then to TMAO by the hepatic enzyme, flavin monooxygenase 3.1, 5”
In the citing paper
“FMO3 has tenfold higher specific activity in the liver than does FMO1 (13).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [13]
In the citing paper
“Most TMA is absorbed into the hepatic portal circulation by passive diffusion across the enterocyte membranes and then is efficiently converted to TMAO by hepatic FMO1 and FMO3 (13); about 95% of TMA is oxidized as it is subsequently excreted in urine in a 3:95 TMA:TMAO ratio (132).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [13]
In the citing paper
“The bile salt, cholic acid, induces FMO3 via the bile acid-activated nuclear receptor FXR (13).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [13]
In the citing paper
“Thus, FMO3 activity is 100 times higher in female than in male mice; more modest gender-related differences are observed in humans (13).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [13]
In the citing paper
“TMA is formed in male ejaculate and vaginal secretions, and as noted in Section 2.2, TMA formation may be regulated by sex hormones (13), and cycle-dependent variations in TMA occur in women (82).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [13]
In the citing paper
“It retains the folded state of proteins and counteracts the effect of denaturants, such as pH, urea, and high pressure (6,13,29).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [13]
In the citing paper
“TMAO is generated via a meta-organismal pathway that begins with gut microbial conversion of dietary nutrients (e.g. phosphatidylcholine, choline, and carnitine) into trimethylamine (TMA), followed by host liver oxidation to TMAO by flavin monooxygenases (FMOs)29,30.”
From Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential (2018) · cites this paper as [30]
In the citing paper
“It has been demonstrated that the gene encoding FMO3 is a direct FXR target gene, and FXR has been found to be a target of sirtuin 1 (SIRT1) in metabolic regulation (23, 34, 35).”
In the citing paper
“It has been demonstrated that the gene encoding FMO3 is a direct FXR target gene, and FXR has been found to be a target of sirtuin 1 (SIRT1) in metabolic regulation (23, 34, 35).”
In the citing paper
“Dietary choline is metabolized by the intestinal microbiota to TMA, which is further metabolized by FMO enzymes, in particular, FMO3, to produce TMAO in the liver (23).”
In the citing paper
“Thus, it is plausible that the decreased levels of TMAO detected in sera of mice colonized with the “core plus all” community (Fig. 1C and Fig. 3A) are caused by increased microbial degradation of cholic acid, which would result in lower levels of fmo3 expression (27).”
From Intestinal Microbiota Composition Modulates Choline Bioavailability from Diet and Accumulation of the Proatherogenic Metabolite Trimethylamine- N -Oxide (2015) · cites this paper as [27]
In the citing paper
“Expression of the main FMO enzyme involved in TMAO production from TMA, FMO3, is induced by bile acids via a mechanism that involves the farnesoid X receptor (FXR) (27).”
From Intestinal Microbiota Composition Modulates Choline Bioavailability from Diet and Accumulation of the Proatherogenic Metabolite Trimethylamine- N -Oxide (2015) · cites this paper as [27]
In the citing paper
“consistent with previous studies in conventionally raised mice which demonstrated that FMO3 is expressed at higher levels in females than in males (8, 27).”
From Intestinal Microbiota Composition Modulates Choline Bioavailability from Diet and Accumulation of the Proatherogenic Metabolite Trimethylamine- N -Oxide (2015) · cites this paper as [27]
In the citing paper
“Specifically, cholic acid stimulates FMO3 expression (27).”
From Intestinal Microbiota Composition Modulates Choline Bioavailability from Diet and Accumulation of the Proatherogenic Metabolite Trimethylamine- N -Oxide (2015) · cites this paper as [27]
In the citing paper
“is downregulated by testosterone (Bennett et al., 2013)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Bennett et al., 2013
In the citing paper
“The TMA produced is then transported to liver via the portal vein and readily metabolized by host hepatic flavin monooxygenases (FMOs) (mainly FMO376) into TMAO9.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [76]
In the citing paper
“Studies by Bennett et al. found that human liver samples from female subjects showed higher FMO1/3 expression, and therefore an increased capacity for TMAO generation, than those from males.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [76]
In the citing paper
“Likewise, gonadectomized male mice treated with testosterone show reduced hepatic FMO3 expression, while ovariectomized female mice treated with estrogen exhibit increases in hepatic FMO3 expression76.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [76]
In the citing paper
“Rodents show a significant sexual dimorphism with respect to FMO3 expression, and TMAO levels, with females showing higher levels (and greater atherosclerosis capacity9, 76).”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [76]
In the citing paper
“Systemic levels of trimethylamine N-oxide (TMAO), a pro-atherogenic and pro-thrombotic metabolite produced from gut microbiota metabolism of dietary trimethylamine (TMA)-containing nutrients such as choline or carnitine, predict incident cardiovascular event risks in stable primary and secondary prevention subjects.”
In the citing paper
“However, it is also clear that in people with adequate renal function, this rise in TMAO is transient.”
From Dietary metabolism, the gut microbiome, and heart failure (2019) · cites this paper as [165]
In the citing paper
“Nonetheless, high dietary fish intakes, especially of deep sea (and cold water) varieties of fish, which are more likely to contain TMAO, is associated with increases in urinary TMAO excretion165.”
From Dietary metabolism, the gut microbiome, and heart failure (2019) · cites this paper as [165]
In the citing paper
“Subsequent studies showed that TMAO is rapidly cleared from the body after ingestion157,165,191.”
From Dietary metabolism, the gut microbiome, and heart failure (2019) · cites this paper as [165]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Self-citationRole of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Benson, A. K., Kelly, S. A., Legge, R., Ma, F., Low, S. J., Kim, J., Zhang, M., Oh, P. L., Nehrenberg, D., Hua, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007028107 · Cited by 1,314
Dumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601056103 · Cited by 1,042 · cited 1×
“Numerous reports in the literature have shown that there is genetic control of the composition of gut flora (Benson et al., 2010; Dumas et al., 2006; Kovacs et al., 2011; Turnbaugh et al., 2010).”
BackgroundMapping the Genetic Architecture of Gene Expression in Human Liver
Schadt, E. E., Molony, C. M., Chudin, E., Hao, K., Yang, X., Lum, P. Y., Kasarskis, A., Zhang, B., Wang, S. S.-M., Suver, C., et al. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060107 · Cited by 918
Self-citationSensing Odorants and Pheromones with Chemosensory Receptors
Touhara, K., & Vosshall, L. B. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163209 · Cited by 585
Krueger, S. K., & Williams, D. E. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.01.001 · Cited by 570
Bhattacharyya, T. (2008) · JAMA · doi:10.1001/jama.299.11.1265 · Cited by 529
Flagged first, then by citations
2 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 1,000
Tenore, G. C., Caruso, D., Buonomo, G., D’Avino, M., Ciampaglia, R., Maisto, M., Schisano, C., Bocchino, B., & Novellino, E. (2019) · Nutrients · doi:10.3390/nu11010122 · Cited by 62
Via, A. D., Gargari, G., Taverniti, V., Rondini, G., Velardi, I., Gambaro, V., Visconti, G. L., Vitis, V. D., Gardana, C., Ragg, E. M., et al. (2019) · Nutrients · doi:10.3390/nu12010062 · Cited by 64
Dietary Regulation of Gut-Brain Axis in Alzheimer’s Disease: Importance of Microbiota Metabolites
Frausto, D. M., Forsyth, C. B., Keshavarzian, A., & Voigt, R. M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.736814 · Cited by 61
Systems Epidemiology: A New Direction in Nutrition and Metabolic Disease Research
Cornelis, M. C., & Hu, F. B. (2013) · Current Nutrition Reports · doi:10.1007/s13668-013-0052-4 · Cited by 64
Lv, Z., Shan, X., Tu, Q., Wang, J., Chen, J., & Yang, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111100 · Cited by 61
Balancing the Equation: A Natural History of Trimethylamine and Trimethylamine-N-oxide
Loo, R. L., Chan, Q. M., Nicholson, J. K., & Holmes, E. C. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00851 · Cited by 63
Xie, Y., Hu, X.-F., Li, S., Qiu, Y., Cao, R., Xu, C., Lu, C., Wang, Z., & Yang, J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106161 · Cited by 62
Self-citationGut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases
Mutalub, Y. B., Abdulwahab, M., Mohammed, A., Yahkub, A. M., Al-Mhanna, S. B., Yusof, W., Tang, S. P., Rasool, A. H. G., & Mokhtar, S. S. (2022) · Foods · doi:10.3390/foods11172575 · Cited by 64
Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities
Hul, M. V., Neyrinck, A. M., Everard, A., Abot, A., Bindels, L. B., Delzenne, N. M., Knauf, C., & Cani, P. D. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00045-23 · Cited by 60
Nutrition and the science of disease prevention: a systems approach to support metabolic health
Bennett, B. J., Hall, K. D., Hu, F. B., McCartney, A. L., & Roberto, C. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12945 · Cited by 63
Self-citationBuchner, D. A., & Nadeau, J. H. (2015) · Genome Research · doi:10.1101/gr.187450.114 · Cited by 64
Sequence meets function—microbiota and cardiovascular disease
Kim, M., Huda, M. N., & Bennett, B. J. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab030 · Cited by 62
Self-citationMetabolomics and lipidomics strategies in modern drug discovery and development
Astarita, G., Kelly, R. S., & Lasky-Su, J. A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103751 · Cited by 63
Ganz, A. B., Cohen, V. V., Swersky, C. C., Stover, J. A., Vitiello, G. A., Lovesky, J., Chuang, J. C., Shields, K. S., Fomin, V. G., Lopez, Y. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020252 · Cited by 62
Cross-Talk between Gut Microbiota and Heart via the Routes of Metabolite and Immunity
Bu, J., & Wang, Z. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/6458094 · Cited by 59
Self-citationThe role of trimethylamine‐N‐Oxide in the development of Alzheimer's disease
Buawangpong, N., Pinyopornpanish, K., Siri‐Angkul, N., Chattipakorn, N., & Chattipakorn, S. C. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30646 · Cited by 59
Zhu, J., & He, L. (2024) · Microorganisms · doi:10.3390/microorganisms12040642 · Cited by 60
Genetic regulation of mouse liver metabolite levels
Ghazalpour, A., Bennett, B. J., Shih, D. M., Che, N., Orozco, L. D., Pan, C., Hagopian, R., He, A., Kayne, P. S., Yang, W.-P., et al. (2014) · Molecular Systems Biology · doi:10.15252/msb.20135004 · Cited by 57
Self-citationTrimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD
Li, X., Hong, J. W., Wang, Y., Pei, M., Wang, L., & Gong, Z. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.733507 · Cited by 59
Trimethylamine N-Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet
Moraes, C., Fouque, D. P., Amaral, A. C. F., & Mafra, D. (2015) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2015.06.004 · Cited by 57
The Microbiota, Chemical Symbiosis, and Human Disease
Redinbo, M. R. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.011 · Cited by 58
Yamagata, K., Hashiguchi, K., Yamamoto, H., & Tagami, M. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000747 · Cited by 57
Luo, T., Guo, Z., Liu, D., Guo, Z., Wu, Q., Li, Q., Lin, R., Chen, P., Ou, C., & Chen, M. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2077602 · Cited by 56
Bile salts in control of lipid metabolism
Schonewille, M., de Boer, J. F., & Groen, A. K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000303 · Cited by 58
Chen, S. X., Jiang, P., Yu, D., Liao, G., Wu, S., Fang, A., Chen, P., Wang, X., Luo, Y., Long, J., et al. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02278-1 · Cited by 58
DiNicolantonio, J. J., McCarty, M. F., & O’Keefe, J. H. (2019) · Open Heart · doi:10.1136/openhrt-2018-000890 · Cited by 59
Li, Y., Ji, X., Wu, H., Xiang, L., Zhang, H., & Tang, D. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114207 · Cited by 55
Singh, V. K., Hu, X.-H., Singh, A. K., Solanki, M. K., Vijayaraghavan, P., Srivastav, R., Joshi, N. K., Kumari, M., Singh, S. K., Wang, Z., et al. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1427608 · Cited by 58
Self-citationExploring the microbiome in health and disease
Scotti, E., Boué, S., Sasso, G. L., Zanetti, F., Belcastro, V., Poussin, C., Sierro, N., Battey, J. N. D., Gimalac, A., Ivanov, N. V., et al. (2017) · Toxicology Research and Application · doi:10.1177/2397847317741884 · Cited by 56
Barton, S., Navarro, S. L., Buas, M. F., Schwarz, Y., Gu, H., Djukovic, D., Raftery, D., Kratz, M., Neuhouser, M. L., & Lampe, J. W. (2015) · Food & Function · doi:10.1039/c5fo00287g · Cited by 55
Microbiota and Hypertension: Role of the Sympathetic Nervous System and the Immune System
Robles‐Vera, I., Toral, M., & Duarte, J. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa103 · Cited by 57
Goh, Y. Q., Cheam, G., & Wang, Y. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c03077 · Cited by 58
Structure, functions, and diversity of the healthy human microbiome
Ahrodia, T., Das, S., Bakshi, S., & Das, B. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.07.003 · Cited by 55
Functional genomic and metagenomic approaches to understanding gut microbiota–animal mutualism
Yoon, S. S., Kim, E.-K., & Lee, W. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.01.007 · Cited by 54
Microbiota-derived Trimethylamine N-oxide Predicts Cardiovascular Risk After STEMI
Matsuzawa, Y., Nakahashi, H., Konishi, M., Sato, R., Kawashima, C., Kikuchi, S., Akiyama, E., Iwahashi, N., Maejima, N., Okada, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48246-6 · Cited by 54
Garcia, E., Osté, M. C. J., Bennett, D. W., Jeyarajah, E. J., SHALAUROVA, I. Y., Gruppen, E. G., Hazen, S. L., Otvos, J. D., Bakker, S. J. L., Dullaart, R. P. F., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111813 · Cited by 54
Self-citationDynamic Changes in the Gut Microbiome at the Acute Stage of Ischemic Stroke in a Pig Model
Jeon, J. H., Lourenco, J. M., Kaiser, E. E., Waters, E. S., Scheulin, K. M., Fang, X., Kinder, H. A., Platt, S. R., Rothrock, M. J., Callaway, T. R., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.587986 · Cited by 55
Alzheimer’s disease and gut microbiota: does trimethylamine N-oxide (TMAO) play a role?
Arrona Cardoza, P., Spillane, M. B., & Morales Marroquin, E. (2022) · Nutrition Reviews · doi:10.1093/nutrit/nuab022 · Cited by 53
Mohammadi, A., Najar, A. G., Yaghoobi, M. M., Jahani, Y., & Vahabzadeh, Z. (2016) · Inflammation · doi:10.1007/s10753-015-0261-7 · Cited by 53
Li, Y., Lü, H., Guo, J., Zhang, M., Zheng, H., Liu, Y., & Liu, W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2215542 · Cited by 54
Li, Z., Yuan, H., Chu, H., & Yang, L. (2023) · Microorganisms · doi:10.3390/microorganisms11082059 · Cited by 55
Dietary Fiber and Its Potential Role in Obesity: A Focus on Modulating the Gut Microbiota
Tian, S., Chu, Q., Ma, S., Ma, H., & Song, H. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c03923 · Cited by 53
Flavonoids, gut microbiota and cardiovascular disease: Dynamics and interplay
Mansour, H., Slika, H., Nasser, S. A., Pintus, G., Khachab, M. Y., Sahebkar, A., & Eid, A. H. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107452 · Cited by 54
Synthesizing Systems Biology Knowledge from Omics Using Genome‐Scale Models
Dahal, S., Yurkovich, J. T., Xu, H., Palsson, B. Ø., & Yang, L. (2020) · PROTEOMICS · doi:10.1002/pmic.201900282 · Cited by 55
The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis
Wang, Z., Hazen, J. E., Jia, X., Org, E., Zhao, Y., Osborn, L. J., Nimer, N. A., Buffa, J. A., Culley, M. K., Krajcik, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413477 · Cited by 52
Self-citationLiu, D., Gu, S., Zhou, Z., Ma, Z., & Zuo, H. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13572 · Cited by 52
Wu, G., Zhang, W., & Li, H. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112057 · Cited by 52
Gut Microbiota, the Genome, and Diet in Atherogenesis
Loscalzo, J. (2013) · New England Journal of Medicine · doi:10.1056/nejme1302154 · Cited by 52
Voigt, R. M., Wang, Z., Brown, J. M., Engen, P. A., Naqib, A., Goetz, C. G., Hall, D. A., Metman, L. V., Shaikh, M., Forsyth, C. B., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105780 · Cited by 51
Self-citationPrognostic Value of Plasma Trimethylamine N-Oxide Levels in Patients with Acute Ischemic Stroke
Zhai, Q., Wang, X., Chen, C., Tang, Y., Wang, Y., Tian, J., Zhao, Y., & Liu, X. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00714-3 · Cited by 53
Gessner, A., di Giuseppe, R., Koch, M., Fromm, M. F., Lieb, W., & Maas, R. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1146 · Cited by 51
Canale, M. P., Noce, A., Lauro, M. D., Marrone, G., Cantelmo, M., Cardillo, C., Federici, M., Daniele, N. D., & Tesauro, M. (2021) · Nutrients · doi:10.3390/nu13041162 · Cited by 51
Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
Li, C., Yang, J., Wang, Y., Qi, Y., Yang, W., & Li, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01247 · Cited by 51
The gut microbiota-artery axis: A bridge between dietary lipids and atherosclerosis?
Zhang, Q., Zhang, L., Chen, C., Li, P., & Lu, B. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101209 · Cited by 50
Decreased Serum Bilirubin Is Associated With Silent Cerebral Infarction
Li, R.-Y., Cao, Z., Zhang, J., Li, Y., & Wang, R. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.303003 · Cited by 50
Zuo, K., Liu, X., Wang, P., Jiao, J., Han, C., Liu, Z., Yin, X., Li, J., & Yang, X. (2020) · BMC Genomics · doi:10.1186/s12864-020-06944-w · Cited by 50
Zhang, L., XIE, F., Tang, H., ZHANG, X., Hu, J., Zhong, X., Gong, N., Lai, Y., Zhou, M., Tian, J., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.10.001 · Cited by 49
Gut microbial metabolism in Alzheimer's disease and related dementias
Kang, J. W., Vemuganti, V., Kuehn, J. F., Ulland, T. K., Rey, F. E., & Bendlin, B. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00470 · Cited by 53
Targeting the Microbiome in Heart Failure
Zabell, A., & Tang, W. H. W. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0528-4 · Cited by 48
Uremic toxins are conditional danger- or homeostasis-associated molecular patterns
Li, R. (2017) · Frontiers in bioscience · doi:10.2741/4595 · Cited by 48
Gut microbiota: a promising target against cardiometabolic diseases
Warmbrunn, M. V., Herrema, H., Aron‐Wisnewsky, J., Soeters, M. R., van Raalte, D. H., & Nieuwdorp, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1720511 · Cited by 49
Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value
Li, X., Fan, Z., Cui, J., Li, D., Lu, J., Cui, X., Xie, L., Wu, Y., Lin, Q., & Li, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.817396 · Cited by 47
Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis
Jang, J. W., Capaldi, E., Smith, T. L., Verma, P., Varga, J., & Ho, K. J. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00895-8 · Cited by 48
Li, D. Y., & Tang, W. H. W. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.01.008 · Cited by 48
Burton, K. J., Krüger, R., Scherz, V., Münger, L. H., Picone, G., Vionnet, N., Bertelli, C., Greub, G., Capozzi, F., & Vergères, G. (2020) · Nutrients · doi:10.3390/nu12010234 · Cited by 48
Yu, Z., Zhang, L., Jiang, X., Xue, C., Chi, N., Zhang, T., & Wang, Y. (2020) · Journal of Food Science · doi:10.1111/1750-3841.15186 · Cited by 47
TMAO Is Both a Biomarker and a Renal Toxin
Fogelman, A. M. (2015) · Circulation Research · doi:10.1161/circresaha.114.305680 · Cited by 48
Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease
Gabriel, C. L., & Ferguson, J. F. (2023) · Circulation Research · doi:10.1161/circresaha.123.322055 · Cited by 51
Microbiota in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Guan, D., Wang, Z., Li, X., Dong, S., Huang, J., & Zhou, W. (2023) · MedComm · doi:10.1002/mco2.417 · Cited by 47
Self-citationLim, T., Ryu, J., Lee, K., Park, S. Y., & Hwang, K. T. (2020) · Nutrients · doi:10.3390/nu12082448 · Cited by 47
Trimethylamine/Trimethylamine-N-Oxide as a Key Between Diet and Cardiovascular Diseases
He, S., Jiang, H., Zhuo, C., & Jiang, W. (2021) · Cardiovascular Toxicology · doi:10.1007/s12012-021-09656-z · Cited by 46
Yadav, H., Jaldhi, Bhardwaj, R., Anamika, A., Bakshi, A., Gupta, S., & Maurya, S. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122022 · Cited by 47
Petriello, M. C., Hoffman, J. B., Sunkara, M., Wahlang, B., Perkins, J. T., Morris, A. J., & Hennig, B. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.03.016 · Cited by 47
Liu, S., He, F., Zheng, T., Wan, S., Chen, J., Yang, F., Xu, X., & Pei, X. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100014 · Cited by 45
Haissman, J. M., Haugaard, A. K., Ostrowski, S. R., Berge, R. K., Hov, J. R., Trøseid, M., & Nielsen, S. D. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2547-x · Cited by 45
Li, Z., & Suslick, K. S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b00995 · Cited by 44
Ringseis, R., Keller, J., & Eder, K. (2018) · Journal of Animal Physiology and Animal Nutrition · doi:10.1111/jpn.12959 · Cited by 47
Biliopancreatic Diversion Induces Greater Metabolic Improvement Than Roux-en-Y Gastric Bypass
Harris, L.-A. L. S., Kayser, B. D., Cefalo, C., Marini, L., Watrous, J. D., Ding, J., Jain, M., McDonald, J. G., Thompson, B. M., Fabbrini, E., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.002 · Cited by 46
Metabolomic profiles associated with all-cause mortality in the Women’s Health Initiative
Balasubramanian, R., Paynter, N. P., Giulianini, F., Manson, J. E., Zhao, Y., Chen, J.-C., Vitolins, M. Z., Albert, C. A., Clish, C., & Rexrode, K. M. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyz211 · Cited by 45
Meinitzer, S., Baranyi, A., Holasek, S. J., Schnedl, W. J., Zelzer, S., Mangge, H., Herrmann, M., Meinitzer, A., & Enko, D. (2020) · Disease Markers · doi:10.1155/2020/7897240 · Cited by 44
Association of Gut Microbiota-Dependent Metabolite Trimethylamine N-Oxide with First Ischemic Stroke
Sun, T., Zhang, Y., Yin, J., Peng, X., Zhou, L., Huang, S., Wen, Y., Cao, B., Chen, L., Li, X., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.55962 · Cited by 44
Pathogenic Mechanisms of Trimethylamine N-Oxide-induced Atherosclerosis and Cardiomyopathy
Zheng, Y., & He, J. (2021) · Current Vascular Pharmacology · doi:10.2174/1570161119666210812152802 · Cited by 46
Trimethylamine-N-oxide and cerebral stroke risk: A review
Dolkar, P., Deyang, T., Anand, N., Rathipriya, A. G., Hediyal, T. A., Vichitra, C., Krishnamoorthy, N. K., Gorantla, V. R., Bishir, M., Rashan, L. J., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106423 · Cited by 46
Intestinal Microbiota Metabolism and Atherosclerosis
Liu, T.-X., Niu, H.-T., & Zhang, S.-Y. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.167362 · Cited by 43
Haissman, J. M., Knudsen, A., Hoel, H., Kjær, A., Kristoffersen, U. S., Berge, R. K., Katzenstein, T. L., Svardal, A. M., Ueland, T., Aukrust, P., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000843 · Cited by 43
The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
Hartiala, J., Schwartzman, W. S., Gabbay, J., Ghazalpour, A., Bennett, B. J., & Allayee, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0641-6 · Cited by 44
Self-citationTrenteseaux, C., Gaston, A., Aguesse, A., Poupeau, G., de Coppet, P., Andriantsitohaina, R., Khallou‐Laschet, J., Amarger, V., Krempf, M., Nobécourt, E., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309923 · Cited by 43
Sánchez‐Tapia, M., Hernández-Velázquez, I., Pichardo‐Ontiveros, E., Granados‐Portillo, O., Mariscal, A. G., Tovar, A. R., & Torres, N. (2020) · Nutrients · doi:10.3390/nu12041182 · Cited by 48
Prajapati, S. K., Shah, R., Alford, N., Mishra, S. P., Jain, S., HANSEN, B. C., Sanberg, P. R., Molina, A. J. A., & Yadav, H. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad226 · Cited by 42
Smallwood, T., Allayee, H., & Bennett, B. J. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000259 · Cited by 42
Self-citationUse of dietary phytochemicals for inhibition of trimethylamine N-oxide formation
Iglesias‐Carres, L., Hughes, M. D., Steele, C. N., Ponder, M. A., Davy, K. P., & Neilson, A. P. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108600 · Cited by 43
Dietary Modification of the Microbiome Affects Risk for Cardiovascular Disease
Mendelsohn, A. R., & Larrick, J. W. (2013) · Rejuvenation Research · doi:10.1089/rej.2013.1447 · Cited by 41
Wilcox, J. D., Skye, S. M., Graham, B., Zabell, A., Li, X. S., Li, L., Shelkay, S., Fu, X., Neale, S., OʼLaughlin, C., et al. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.03.016 · Cited by 44
Self-citationWu, H., Chen, J., Guo, S., Deng, J., Zhou, Z., Zhang, X., Qi, T., Yu, F., & Yang, Q. L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2500099 · Cited by 42
An analysis of a ‘community-driven’ reconstruction of the human metabolic network
Swainston, N., Mendes, P., & Kell, D. B. (2013) · Metabolomics · doi:10.1007/s11306-013-0564-3 · Cited by 42
Huang, F., Zhang, F., Xu, D., Zhang, Z., Xu, F., Tao, X., Qiu, L., & Wei, H. (2018) · Journal of Dairy Science · doi:10.3168/jds.2017-13713 · Cited by 41
Antibiotic Treatment Protocols and Germ-Free Mouse Models in Vascular Research
Bayer, F., Ascher, S., Pontarollo, G., & Reinhardt, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02174 · Cited by 44
The remodel of the “central dogma”: a metabolomics interaction perspective
dos Santos, G. C., Renovato‐Martins, M., & de Brito, N. M. (2021) · Metabolomics · doi:10.1007/s11306-021-01800-8 · Cited by 48
Chronic consumption of food-additives lead to changes via microbiota gut-brain axis
de Abiega-Franyutti, P., & Freyre‐Fonseca, V. (2021) · Toxicology · doi:10.1016/j.tox.2021.153001 · Cited by 45
Chen, C., Leu, H., Wang, S., Tsai, S., Chou, R., Lu, Y., Tsai, Y., Kuo, C., Huang, P., Chen, J., et al. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0115 · Cited by 41
Metadata
- Authors
- Bennett, B. J., Vallim, T. Q. D. A., Wang, Z., Shih, D. M., Meng, Y., Gregory, J., Allayee, H., Lee, R., Graham, M., Crooke, R., Edwards, P. A., Hazen, S. L., & Lusis, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Cleveland Clinic (US)
- University of Southern California (US)
- Corresponding author
- Bennett, Brian J.
- Lusis, Aldons J.
- ORCID
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 17
- Issue
- 1
- Pages
- 49-60
- ISSN
- 1550-4131 (ISSN-L)
- PMC
- PMC3771112
- OpenAlex
- W2046971089
- Cited by
- 1,070
- References
- 35
- Citations by year
- 2026: 75 · 2025: 88 · 2024: 88 · 2023: 95 · 2022: 116 · 2021: 102 · 2020: 107 · 2019: 90 · 2018: 81 · 2017: 50 · 2016: 67 · 2015: 59 · 2014: 32 · 2013: 19
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Cleveland Clinic
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL3 0568, HL28481, R01HL094322, P01HL030568, R00HL102223, K99HL102223, HL113452, P20HL113452, HL94322, K99/R00 HL102223, R01HL103866, HL103866, P01HL028481)
- National Institute of General Medical Sciences (T32GM088088)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Keywords
- trimethylamine N-oxide, atherosclerosis, flavin monooxygenase 3, gut microbiota, choline metabolism, bile acids, farnesoid X receptor, androgen regulation, sex differences, genetic variation, dietary regulation
- MeSH terms
- Receptor, Farnesoid X-Activated, Androgens, Animals, Base Sequence, Bile Acids and Salts, Choline, Diet, Female, Humans, Male, Methylamines, Oxygenases, Sex Factors, Down-Regulation, Receptors, Cytoplasmic and Nuclear, Mice, Knockout, Polymorphism, Single Nucleotide, Gene Silencing, Atherosclerosis, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
